Redx Pharma plc Announces the Appointment of Jane Robertson as Chief Medical Officer, Effective 1 March 2021

Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. The Company’s pipeline includes zelasudil (RXC007), zamaporvint (RXC004) and RXC008. Its lead asset, zelasudil (RXC007), a selective ROCK2 inhibitor, with potential in multiple interstitial lung diseases and cancer-associated fibrosis, is in a Phase 2 clinical program with an initial indication in idiopathic pulmonary fibrosis. RXC008 is a potential GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease. Its oncology pipeline is led by zamaporvint (RXC004), a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy, and its drug discovery engine is advancing a pipeline of research programs and collaborations in both fibrotic diseases and oncology.